{"id":67948,"date":"2026-06-10T22:05:39","date_gmt":"2026-06-10T14:05:39","guid":{"rendered":"https:\/\/flcube.com\/?p=67948"},"modified":"2026-06-10T22:05:41","modified_gmt":"2026-06-10T14:05:41","slug":"neurogen-pharma-secures-nmpa-approval-for-ajovy-fremanezumab-in-china-launching-first-quarterly-cgrp-migraine-prevention-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67948","title":{"rendered":"NeuroGen Pharma Secures NMPA Approval for Ajovy (Fremanezumab) in China, Launching First Quarterly CGRP Migraine Prevention Therapy"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>NeuroGen Pharma<\/strong> announced it has received <strong>marketing approval<\/strong> from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for <strong>Ajovy\u00ae (fremanezumab)<\/strong> for the <strong>preventive treatment of migraine in adults<\/strong>, marking a significant expansion of CGRP-targeted therapies in the Chinese market.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Fremanezumab, originally developed by <strong>Teva Pharmaceutical Industries<\/strong>, is a <strong>monoclonal antibody (mAb)<\/strong> that targets the <strong>calcitonin gene-related peptide (CGRP) ligand<\/strong>, a key mediator in migraine pathophysiology. The therapy offers <strong>two flexible subcutaneous dosing regimens<\/strong>: <strong>225 mg once monthly<\/strong> or <strong>675 mg once quarterly<\/strong>, with the quarterly option representing a major advancement in treatment convenience and adherence for chronic migraine patients.<\/p>\n\n\n\n<h2 id=\"h-product-profile-amp-clinical-differentiation\" class=\"wp-block-heading\">Product Profile &amp; Clinical Differentiation<\/h2>\n\n\n\n<h3 id=\"h-dual-dosing-regimen-advantages\" class=\"wp-block-heading\">Dual Dosing Regimen Advantages<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Regimen<\/th><th>Dose<\/th><th>Frequency<\/th><th>Patient Benefits<\/th><\/tr><\/thead><tbody><tr><td><strong>Monthly<\/strong><\/td><td>225 mg<\/td><td>Once per month<\/td><td>Standard preventive approach<\/td><\/tr><tr><td><strong>Quarterly<\/strong><\/td><td>675 mg<\/td><td>Once every three months<\/td><td><strong>Reduced injection burden<\/strong>, improved adherence, better long-term migraine control<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 id=\"h-mechanism-of-action\" class=\"wp-block-heading\">Mechanism of Action<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target<\/strong>: Calcitonin gene-related peptide (CGRP) ligand neutralization<\/li>\n\n\n\n<li><strong>Pathway<\/strong>: Blocks CGRP binding to its receptor, inhibiting migraine cascade activation<\/li>\n\n\n\n<li><strong>Specificity<\/strong>: Highly selective monoclonal antibody with minimal off-target effects<\/li>\n\n\n\n<li><strong>Administration<\/strong>: Subcutaneous injection with pre-filled pen delivery system<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-clinical-evidence-base\" class=\"wp-block-heading\">Clinical Evidence Base<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pivotal Studies<\/strong>: Multiple Phase III trials demonstrating efficacy and safety in adult migraine prevention<\/li>\n\n\n\n<li><strong>Efficacy Endpoints<\/strong>: Significant reduction in monthly migraine days across episodic and chronic migraine populations<\/li>\n\n\n\n<li><strong>Safety Profile<\/strong>: Well-tolerated with low rates of serious adverse events<\/li>\n\n\n\n<li><strong>Long-term Data<\/strong>: Sustained efficacy and safety demonstrated in extension studies<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-partnership-framework\" class=\"wp-block-heading\">Strategic Partnership Framework<\/h2>\n\n\n\n<h3 id=\"h-april-2026-teva-collaboration\" class=\"wp-block-heading\">April 2026 Teva Collaboration<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Territory<\/strong>: <strong>Exclusive commercialization rights<\/strong> in mainland China<\/li>\n\n\n\n<li><strong>Intellectual Property<\/strong>: Exclusive license to relevant patents and trademarks<\/li>\n\n\n\n<li><strong>Regulatory Status<\/strong>: NeuroGen Pharma designated as <strong>Marketing Authorization Holder (MAH)<\/strong> for mainland China<\/li>\n\n\n\n<li><strong>Development Responsibility<\/strong>: Leveraging Teva&#8217;s established global clinical data package<\/li>\n\n\n\n<li><strong>Commercial Infrastructure<\/strong>: NeuroGen Pharma responsible for China market launch and distribution<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-market-entry-strategy\" class=\"wp-block-heading\">Market Entry Strategy<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover Advantage<\/strong>: Among the first CGRP monoclonal antibodies with quarterly dosing available in China<\/li>\n\n\n\n<li><strong>Pricing Position<\/strong>: Premium pricing reflecting innovative quarterly regimen and established clinical profile<\/li>\n\n\n\n<li><strong>Target Population<\/strong>: Estimated 100+ million migraine sufferers in China, with 30-40 million classified as candidates for preventive therapy<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-opportunity-amp-competitive-landscape\" class=\"wp-block-heading\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<h3 id=\"h-chinese-migraine-market-dynamics\" class=\"wp-block-heading\">Chinese Migraine Market Dynamics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prevalence<\/strong>: Migraine affects approximately 10-15% of Chinese adults<\/li>\n\n\n\n<li><strong>Treatment Gap<\/strong>: Limited access to modern preventive therapies, with most patients relying on traditional medications<\/li>\n\n\n\n<li><strong>CGRP Market<\/strong>: Emerging as premium segment with high growth potential<\/li>\n\n\n\n<li><strong>Quarterly Advantage<\/strong>: Unique positioning as only CGRP mAb offering three-month dosing interval<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-competitive-positioning\" class=\"wp-block-heading\">Competitive Positioning<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dosing Convenience<\/strong>: Quarterly regimen provides significant differentiation versus monthly-only competitors<\/li>\n\n\n\n<li><strong>Global Validation<\/strong>: Leverages Teva&#8217;s extensive international experience and clinical data<\/li>\n\n\n\n<li><strong>Local Expertise<\/strong>: NeuroGen Pharma&#8217;s domestic commercial infrastructure ensures effective market penetration<\/li>\n\n\n\n<li><strong>Regulatory Efficiency<\/strong>: MAH qualification streamlines post-approval regulatory compliance<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-commercial-outlook-amp-revenue-potential\" class=\"wp-block-heading\">Commercial Outlook &amp; Revenue Potential<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Addressable Market<\/strong>: Estimated 5-8 million adult migraine patients suitable for preventive biologic therapy in China<\/li>\n\n\n\n<li><strong>Market Penetration<\/strong>: Expected rapid adoption among neurologists and headache specialists<\/li>\n\n\n\n<li><strong>Revenue Projection<\/strong>: Analysts forecast peak annual sales of $200-300 million in the Chinese market<\/li>\n\n\n\n<li><strong>Franchise Expansion<\/strong>: Success with fremanezumab could facilitate additional Teva partnership opportunities<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This NMPA approval represents a major milestone for NeuroGen Pharma, establishing the company as a key player in China&#8217;s emerging migraine therapeutics market while providing patients with unprecedented treatment flexibility through the quarterly dosing option.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding market adoption, competitive dynamics, regulatory compliance, and revenue projections. Actual results may differ due to reimbursement challenges, competitive pressures, and evolving treatment guidelines.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>NeuroGen Pharma announced it has received marketing approval from China&#8217;s National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":67950,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[4226,15,1071],"class_list":["post-67948","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-neurogen-pharma","tag-product-approvals","tag-teva-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>NeuroGen Pharma Secures NMPA Approval for Ajovy (Fremanezumab) in China, Launching First Quarterly CGRP Migraine Prevention Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"NeuroGen Pharma announced it has received marketing approval from China&#039;s National Medical Products Administration (NMPA) for Ajovy\u00ae (fremanezumab) for the preventive treatment of migraine in adults, marking a significant expansion of CGRP-targeted therapies in the Chinese market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67948\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeuroGen Pharma Secures NMPA Approval for Ajovy (Fremanezumab) in China, Launching First Quarterly CGRP Migraine Prevention Therapy\" \/>\n<meta property=\"og:description\" content=\"NeuroGen Pharma announced it has received marketing approval from China&#039;s National Medical Products Administration (NMPA) for Ajovy\u00ae (fremanezumab) for the preventive treatment of migraine in adults, marking a significant expansion of CGRP-targeted therapies in the Chinese market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67948\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-10T14:05:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-10T14:05:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1003.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67948#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67948\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"NeuroGen Pharma Secures NMPA Approval for Ajovy (Fremanezumab) in China, Launching First Quarterly CGRP Migraine Prevention Therapy\",\"datePublished\":\"2026-06-10T14:05:39+00:00\",\"dateModified\":\"2026-06-10T14:05:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67948\"},\"wordCount\":564,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67948#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1003.webp\",\"keywords\":[\"NeuroGen Pharma\",\"Product approvals\",\"Teva Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67948#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67948\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67948\",\"name\":\"NeuroGen Pharma Secures NMPA Approval for Ajovy (Fremanezumab) in China, Launching First Quarterly CGRP Migraine Prevention Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67948#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67948#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1003.webp\",\"datePublished\":\"2026-06-10T14:05:39+00:00\",\"dateModified\":\"2026-06-10T14:05:41+00:00\",\"description\":\"NeuroGen Pharma announced it has received marketing approval from China's National Medical Products Administration (NMPA) for Ajovy\u00ae (fremanezumab) for the preventive treatment of migraine in adults, marking a significant expansion of CGRP-targeted therapies in the Chinese market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67948#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67948\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67948#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1003.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1003.webp\",\"width\":1080,\"height\":608,\"caption\":\"NeuroGen Pharma Secures NMPA Approval for Ajovy (Fremanezumab) in China, Launching First Quarterly CGRP Migraine Prevention Therapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67948#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeuroGen Pharma Secures NMPA Approval for Ajovy (Fremanezumab) in China, Launching First Quarterly CGRP Migraine Prevention Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NeuroGen Pharma Secures NMPA Approval for Ajovy (Fremanezumab) in China, Launching First Quarterly CGRP Migraine Prevention Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"NeuroGen Pharma announced it has received marketing approval from China's National Medical Products Administration (NMPA) for Ajovy\u00ae (fremanezumab) for the preventive treatment of migraine in adults, marking a significant expansion of CGRP-targeted therapies in the Chinese market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67948","og_locale":"en_US","og_type":"article","og_title":"NeuroGen Pharma Secures NMPA Approval for Ajovy (Fremanezumab) in China, Launching First Quarterly CGRP Migraine Prevention Therapy","og_description":"NeuroGen Pharma announced it has received marketing approval from China's National Medical Products Administration (NMPA) for Ajovy\u00ae (fremanezumab) for the preventive treatment of migraine in adults, marking a significant expansion of CGRP-targeted therapies in the Chinese market.","og_url":"https:\/\/flcube.com\/?p=67948","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-10T14:05:39+00:00","article_modified_time":"2026-06-10T14:05:41+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1003.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67948#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67948"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"NeuroGen Pharma Secures NMPA Approval for Ajovy (Fremanezumab) in China, Launching First Quarterly CGRP Migraine Prevention Therapy","datePublished":"2026-06-10T14:05:39+00:00","dateModified":"2026-06-10T14:05:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67948"},"wordCount":564,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=67948#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1003.webp","keywords":["NeuroGen Pharma","Product approvals","Teva Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67948#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67948","url":"https:\/\/flcube.com\/?p=67948","name":"NeuroGen Pharma Secures NMPA Approval for Ajovy (Fremanezumab) in China, Launching First Quarterly CGRP Migraine Prevention Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=67948#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=67948#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1003.webp","datePublished":"2026-06-10T14:05:39+00:00","dateModified":"2026-06-10T14:05:41+00:00","description":"NeuroGen Pharma announced it has received marketing approval from China's National Medical Products Administration (NMPA) for Ajovy\u00ae (fremanezumab) for the preventive treatment of migraine in adults, marking a significant expansion of CGRP-targeted therapies in the Chinese market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67948#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67948"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=67948#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1003.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1003.webp","width":1080,"height":608,"caption":"NeuroGen Pharma Secures NMPA Approval for Ajovy (Fremanezumab) in China, Launching First Quarterly CGRP Migraine Prevention Therapy"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67948#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"NeuroGen Pharma Secures NMPA Approval for Ajovy (Fremanezumab) in China, Launching First Quarterly CGRP Migraine Prevention Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1003.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67948","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67948"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67948\/revisions"}],"predecessor-version":[{"id":67951,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67948\/revisions\/67951"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/67950"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67948"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67948"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67948"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}